Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Furst

Showing results (121-130 of 755) with videos related to

Pageof 76
Sort By:
Arthritis and Rheumatism|April 13, 2004
Anti-tumor necrosis factor alpha therapy and heart failure: what have we learned and where do we go from here?Dinesh Khanna, Maureen McMahon, Daniel E Furst
Expert Opinion on Drug Metabolism & Toxicology|July 26, 2006
Meloxicam in rheumatoid arthritisMansoor Ahmed, Dinesh Khanna, Daniel E Furst
Lancet (London, England)|May 23, 2006
Systemic sclerosis: hypothesis-driven treatment strategiesChristina Charles, Philip Clements, Daniel E Furst
Current Rheumatology Reports|December 21, 2000
Bone marrow transplantation in the treatment of systemic sclerosisF Viganego, R Nash, D E Furst
Drug Safety|April 6, 2004
Safety of tumour necrosis factor-alpha antagonistsDinesh Khanna, Maureen McMahon, Daniel E Furst
Expert Opinion on Biological Therapy|May 20, 2015
Brodalumab -an IL-17RA monoclonal antibody for psoriasis and psoriatic arthritisErin Bauer, Jessica Lucier, Daniel E Furst
The Journal of Clinical Investigation|July 1, 1977
Salicylate metabolism in twins. Evidence suggesting a genetic influence and induction of salicylurate formationD E Furst, N Gupta, H E Paulus
Clinical and Experimental Rheumatology|November 6, 2010
First Systemic Sclerosis World CongressD E Furst, A Tyndall, M Matucci-Cerinic
Biomedical Instrumentation & Technology|January 1, 1995
Increasing efficiency and effectiveness of user equipment training using manufacturer-provided videotapesE Furst, N R O'Shaughnessy, W F Betts
The Journal of Rheumatology|May 5, 2007
Rationale and strategies for reevaluating the ACR20David T Felson, Daniel E Furst, Maarten Boers
Pageof 76

Showing results (121-130 of 755) with videos related to

Sort By:
Pageof 76
Arthritis and Rheumatism|April 13, 2004
Anti-tumor necrosis factor alpha therapy and heart failure: what have we learned and where do we go from here?Dinesh Khanna, Maureen McMahon, Daniel E Furst
Expert Opinion on Drug Metabolism & Toxicology|July 26, 2006
Meloxicam in rheumatoid arthritisMansoor Ahmed, Dinesh Khanna, Daniel E Furst
Lancet (London, England)|May 23, 2006
Systemic sclerosis: hypothesis-driven treatment strategiesChristina Charles, Philip Clements, Daniel E Furst
Current Rheumatology Reports|December 21, 2000
Bone marrow transplantation in the treatment of systemic sclerosisF Viganego, R Nash, D E Furst
Drug Safety|April 6, 2004
Safety of tumour necrosis factor-alpha antagonistsDinesh Khanna, Maureen McMahon, Daniel E Furst
Expert Opinion on Biological Therapy|May 20, 2015
Brodalumab -an IL-17RA monoclonal antibody for psoriasis and psoriatic arthritisErin Bauer, Jessica Lucier, Daniel E Furst
The Journal of Clinical Investigation|July 1, 1977
Salicylate metabolism in twins. Evidence suggesting a genetic influence and induction of salicylurate formationD E Furst, N Gupta, H E Paulus
Clinical and Experimental Rheumatology|November 6, 2010
First Systemic Sclerosis World CongressD E Furst, A Tyndall, M Matucci-Cerinic
Biomedical Instrumentation & Technology|January 1, 1995
Increasing efficiency and effectiveness of user equipment training using manufacturer-provided videotapesE Furst, N R O'Shaughnessy, W F Betts
The Journal of Rheumatology|May 5, 2007
Rationale and strategies for reevaluating the ACR20David T Felson, Daniel E Furst, Maarten Boers
Pageof 76